Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Kratom Industry GMPs Target Swaying FDA By Exceeding Agency Standards

Sep 19 2018

• By Eileen Francis

Related Content

DEA Proposal To Schedule Kratom Stirs Wave Of Opposition

Dec 08 2016

Kratom Group Contests FDA's Opioid Finding, Requests Joint Meeting With NIDA

Aug 16 2018

Salmonella In Kratom, Like Use Of The Herb, Exceeds FDA Expectations

Jul 02 2018

Warnings On Kratom Opioid Withdrawal Claims Mark Tip Of FDA Concerns

Sep 11 2018

Kratom Experts Seek NIDA As Ally To Show Herb's Safety And Benefits

Nov 28 2017

FDA Turns Kratom's Future In US Dietary Supplement Market Into History

Nov 15 2017

Additional Topics

United States Advertising, Marketing & Sales FDA Dietary Supplements Safety Consumer

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window